Literature DB >> 14666890

First biologic for allergy-related asthma.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14666890

Source DB:  PubMed          Journal:  FDA Consum        ISSN： 0362-1332


× No keyword cloud information.
  2 in total

1.  Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.

Authors:  Luciana Kase Tanno; Pascal Demoly; Bryan Martin; Jonathan Berstein; Mario Morais-Almeida; Michael Levin; Alessandro Fiocchi; Mario Sánchez-Borges; Luis R Caraballo; Gary Wong; José Antonio Ortega-Martell; Philip Rouadi; Anahí Yáñez; Liang Lu Wang; David B Peden; Manana Chikhladze; Sandra N González-Díaz; Jean-François Fontaine; James Sublett; Yoon-Seok Chang; Giovanni Passalacqua; Ignacio J Ansotegui; Motohiro Ebisawa; Gianenrico Senna; Marco Caminati
Journal:  World Allergy Organ J       Date:  2021-01-31       Impact factor: 4.084

2.  Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life.

Authors:  Francesco Menzella; Matteo Fontana; Marco Contoli; Patrizia Ruggiero; Carla Galeone; Silvia Capobelli; Anna Simonazzi; Chiara Catellani; Chiara Scelfo; Claudia Castagnetti; Francesco Livrieri; Nicola Facciolongo
Journal:  J Asthma Allergy       Date:  2022-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.